VCYT · Veracyte, Inc. · Stock research

2026-08-15 refresh.

Current Thesis

The 2026-07-19 note put two conditions on the table: a weekly close below $50 would mark the July breakout as failed, and the 2026-07-30 Q2 print was the dated binary. Both resolved against the continuation case. Veracyte beat on the quarter — total revenue $150.3M (+15% YoY), testing revenue $145.7M (+19%), adjusted EBITDA $44M at 29.2% of revenue — and still lost roughly a third of its market value inside three weeks, closing $41.25 on 2026-08-14, 31.8% under the $60.49 52-week high, with RSI(14) at 24.6.

What broke was the growth shape, not the P&L. Decipher revenue growth halved from +30% YoY in Q1 to +20% in Q2, and management cut roughly 1,000 tests from 2026 Decipher volume guidance, attributing it to the 2024 NCCN guideline change that removed genomic testing from low-risk active surveillance. FY26 revenue guidance went up in absolute terms — $590–596M from $582–592M — but the $593M midpoint landed under the ~$598M consensus. TrueMRD, the launch that carried the July re-rating, was confirmed to have no revenue contribution expected in 2026; Prosigna is commercially live but excluded from guidance pending MolDX technical assessment and final pricing. The desks that marked targets up 20–43% between 2026-07-09 and 2026-07-15 marked them back down on 2026-08-03/04.

The narrative leg an investor would be buying here is different from the one that worked in July. It is no longer "sell-side is chasing an under-followed compounder." It is "a 29%-EBITDA-margin diagnostics business with $485.2M in cash and short-term investments de-rated 32% over a $5M guidance-midpoint shortfall, with two unmonetized product lines sitting outside the numbers." That is a valuation-reversion argument, and it currently has no dated event to force it.

Bullish and bearish views on Veracyte, Inc.

The model's bull view on Veracyte, Inc. (VCYT), in brief: Q2 2026 (2026-07-30) was an operational beat: total revenue $150.3M (+15% YoY), testing revenue $145.7M (+19%), GAAP net income $25.5M, adjusted EBITDA $44M (+23% YoY, 29.2% of revenue). The bear view: The growth-rate step-down is the whole story. Both cases follow in full.

Bull Case

• Q2 2026 (2026-07-30) was an operational beat: total revenue $150.3M (+15% YoY), testing revenue $145.7M (+19%), GAAP net income $25.5M, adjusted EBITDA $44M (+23% YoY, 29.2% of revenue). Cash, equivalents and short-term investments $485.2M.
• Guidance moved up, not down: FY26 total revenue guided $590–596M (14–15% growth) versus the prior $582–592M; testing revenue $576–582M (17–18%); adjusted EBITDA margin guided above 26%. The de-rating is against a consensus number, not against a cut.
• Decipher volume still grew: ~30,000 tests in Q2 with volume +17% YoY and revenue +20%. Afirma ran ~18,600 tests (+10% YoY) with revenue +18%.
• Two launches carry zero in the model: Prosigna is live in the U.S. with management citing engagement from over 100 institutions, and its revenue is excluded from FY26 guidance until MolDX technical review and final pricing conclude. TrueMRD (Medicare coverage 2026-05-15, launch 2026-06-01) is guided to no 2026 revenue. Anything either delivers in 2027 is incremental to the current base.
• Price sits below every published target after the cuts: Piper Sandler Overweight $54 and Stephens Overweight $55 (both 2026-08-04), Canaccord Hold $50 (2026-08-03), and Morgan Stanley's Underweight $44 (2026-08-04) are all above the 2026-08-14 close of $41.25. The tape is currently more negative than the most negative desk covering the name.

Bear Case

• The growth-rate step-down is the whole story. Total revenue growth went +21% YoY in Q1 (reported 2026-05-05) to +15% in Q2. Decipher revenue went +30% to +20%. Two quarters is a short series, but the direction was accompanied by a volume guidance cut, which is management's own confirmation rather than a modelling artifact.
• The Decipher headwind is structural. The 2024 NCCN change removing genomic testing from low-risk active surveillance shrinks an addressable pool; it does not defer it. The ~1,000-test guidance reduction is small in dollars and large in what it says about the highest-multiple part of the franchise.
• The optionality that justified the July multiple is a 2027 event. TrueMRD: no 2026 revenue. Prosigna: reimbursement and EMR-integration headwinds flagged on the 2026-07-30 call, pricing unresolved. An investor paying a July multiple was paying for near-term monetization that management has now dated further out.
• Analyst target round-trip inside a month. Piper initiated Overweight $66 on 2026-07-15 and cut to $54 on 2026-08-04. Canaccord lifted Hold $42→$60 on 2026-07-14 and cut to $50 on 2026-08-03. Stephens went $68→$55. Targets that move 20–43% up and then back down in three weeks describe a coverage base with low conviction in its own numbers.
• Insider context: CFO Rebecca Chambers filed a Form 4 for 3,561 shares sold at an average $49.73 on 2026-06-04 — above the current tape, so not predictive, but it establishes the pattern of selling into strength.

Setup & Price Structure

The narrative is dead, dated by the 2026-07-30 print and the 2026-08-03/04 target cuts. The specific narrative leg — sell-side capitulation into an accelerating TrueMRD/Decipher story — failed on a stated schedule and the structure that carried it is gone. A dead narrative is not a dead company here; the P&L kept compounding through the break.

Observables as of the 2026-08-14 close of $41.25:

• -31.8% from the 52-week high $60.49, achieved in roughly three weeks from the mid-July peak area.
• The June $49–52 shelf, named in the prior note as the structural floor, is gone. The weekly-close-below-$50 condition published on 2026-07-19 triggered.
• RSI(14) 24.6 — deeply oversold on the daily, with no base yet built. Oversold is a condition, not a signal; nothing in the tape yet shows the selling absorbed.
• The three-month return is still +7.2%, so the drawdown has retraced the July leg without yet retracing the spring advance.
• No dated forcing event inside the window. Q2 is reported, Q3 is not scheduled, and the next public appearance is a fireside chat on 2026-09-15. A stock this far below its high with nothing scheduled has to rebuild demand without a headline to do it.

Positioning evidence points one way and price points the other: four desks cut targets on 2026-08-03/04 and price then went through all four marks, including a $44 Underweight. That gap gets closed either by price recovering toward the cut targets or by a second round of cuts.

Catalyst Calendar (next 30 days)

• 2026-09-15 — Morgan Stanley 24th Annual Global Healthcare Conference, fireside chat 5:35pm ET, New York (announced 2026-07-28). Day 31 from this note, and the only scheduled management appearance on the calendar. The gradeable content is whether Prosigna MolDX pricing status or Decipher volume trend gets updated between quarters.
• ~2026-10-29 (est.) — Q3 2026 results. Date unconfirmed by the company; Q2 was reported 2026-07-30 after close. This is the first checkpoint on whether the Decipher deceleration to +20% stabilizes.
• No date set — Prosigna MolDX technical assessment and final Medicare pricing. Management excluded Prosigna from FY26 guidance pending this; a determination is the single event that could re-open a growth leg without waiting for a print.

Elapsed catalysts

• 2026-08-11 — investor conference appearance (elapsed). Passed without a reported change to guidance or coverage. (passed 15d ago)

What Would Change Our Mind

The structure that defined this name for three months is already lost — the June $49–52 shelf gave way after the print, and the prior note's break condition triggered. What remains open is whether the post-print reset is absorption or the first half of a full round-trip.

A weekly close below $38 resolves that against the reversion case: it would take out the spring advance the drawdown has so far left intact (three-month return was still +7.2% on 2026-08-14) and would mark the move as distribution rather than a washout. A second confirmation would be the 2026-09-15 fireside passing with no update on Prosigna MolDX pricing and no evidence Decipher volume growth has stabilized above the +17% posted in Q2.

The read flips the other way on a weekly close back above $50 that reclaims the June shelf, or on Q3 (est. ~2026-10-29) showing Decipher revenue growth re-accelerating from +20% alongside a Prosigna pricing determination that lets management put it inside guidance. Absent one of those, the case rests on multiple compression alone, which is the weakest form of this argument.

Correlation Notes

• MRD/genomics cohort: NTRA, EXAS, GH. Natera's MRD commentary moves VCYT directly now that TrueMRD is launched, and the guidance that TrueMRD contributes no 2026 revenue makes VCYT the least MRD-levered of the group this year — relevant when the cohort trades on an MRD headline.
• Shared single point of failure: CMS/MolDX reimbursement policy and NCCN guideline revisions. The 2024 NCCN active-surveillance change is the direct cause of the Q2 Decipher volume cut; the same process governs every classifier in the cohort.
• Beta: trades with XBI/IBB risk appetite on macro days, but the July–August move was idiosyncratic — driven by the 2026-07-30 guidance midpoint and the 2026-08-03/04 target cuts, not a sector drawdown.
• Prosigna read-across: breast-cancer genomic profiling puts it against Exact Sciences' Oncotype DX; MolDX pricing on Prosigna is a competitive datapoint for both.